RGLS · Regulus Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.82M | - | $11.35M | $8.31M | $6.04M | - | $5.49M | $4.98M | $4.92M | - |
| SG&A | $3.72M | - | $3.86M | $3.95M | $2.79M | - | $2.64M | $2.34M | $2.44M | - |
| Total Operating Expenses | $10.54M | - | $15.21M | $12.26M | $8.83M | - | $8.13M | $7.32M | $7.37M | - |
| D&A | $85.0K | - | - | - | $81.0K | - | - | - | $48.0K | - |
| Operating Income | ($10.54M) | - | ($15.21M) | ($12.26M) | ($8.83M) | - | ($8.13M) | ($7.32M) | ($7.37M) | - |
| Interest Expense | $81.0K | - | $137.0K | $168.0K | $81.0K | - | $137.0K | $168.0K | $185.0K | - |
| Income Tax | - | - | $0 | $1.0K | - | - | $0 | $1.0K | $0 | - |
| Net Income | ($9.63M) | - | ($14.06M) | ($11.04M) | ($8.47M) | - | ($7.82M) | ($7.01M) | ($7.14M) | - |
| EPS - Basic | ($0.15) | - | ($0.21) | ($0.17) | ($0.29) | - | ($0.40) | ($0.37) | ($0.42) | - |
| EPS - Diluted | ($0.15) | - | ($0.21) | ($0.17) | ($0.29) | - | ($0.40) | ($0.37) | ($0.42) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.46M | $38.53M | $26.37M | $17.12M | $29.59M | $23.77M | $25.83M | $37.26M | $30.31M | $24.23M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $200.0K | $947.0K | $792.0K | $601.0K | $406.0K | $204.0K | $599.0K | $362.0K | $581.0K | $175.0K |
| Current Assets | $71.69M | $82.34M | $91.69M | $100.34M | $101.45M | $28.18M | $35.08M | $41.36M | $34.56M | $44.08M |
| Total Assets | $74.83M | $84.18M | $93.76M | $104.12M | $114.14M | $30.75M | $37.75M | $43.65M | $37.02M | $46.72M |
| Current Liabilities | $4.40M | $7.50M | $6.48M | $5.26M | $5.68M | $8.51M | $8.25M | $8.23M | $8.82M | $11.66M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $0 |
| Total Liabilities | $5.80M | $7.77M | $6.96M | $5.94M | $6.55M | $9.56M | $9.49M | $9.65M | $10.42M | $13.43M |
| Stockholders' Equity | $69.03M | $76.41M | $86.81M | $98.18M | $107.59M | $21.19M | $28.26M | $34.00M | $26.59M | $33.29M |
| Retained Earnings | ($569.21M) | ($559.57M) | ($546.78M) | ($532.72M) | ($521.68M) | ($513.21M) | ($505.15M) | ($497.33M) | ($490.31M) | ($483.18M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.61M) | - | - | - | ($8.74M) | - | - | - | ($8.11M) | - |
| Investing Cash Flow | $21.50M | - | - | - | ($78.54M) | - | - | - | $15.00M | - |
| Financing Cash Flow | $45.0K | - | - | - | $93.11M | - | - | - | ($805.0K) | - |
| CapEx | $0 | - | - | - | $229.0K | - | - | - | $1.0K | - |
| Free Cash Flow | ($10.61M) | - | - | - | ($8.97M) | - | - | - | ($8.12M) | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.10 | - | - | - | 1.06 | - | - | - | 1.14 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.9% | - | -15.0% | -10.6% | -7.4% | - | -20.7% | -16.1% | -19.3% | - |
| Return on equity | -14.0% | - | -16.2% | -11.2% | -7.9% | - | -27.7% | -20.6% | -26.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 16.31 | 10.98 | 14.14 | 19.06 | 17.85 | 3.31 | 4.25 | 5.03 | 3.92 | 3.78 |
| Quick ratio | 16.31 | 10.98 | 14.14 | 19.06 | 17.85 | 3.31 | 4.25 | 5.03 | 3.92 | 3.78 |
| Cash ratio | 11.25 | 5.14 | 4.07 | 3.25 | 5.21 | 2.79 | 3.13 | 4.53 | 3.44 | 2.08 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -130.1x | - | -111.0x | -73.0x | -109.0x | - | -59.3x | -43.5x | -39.8x | - |
| Equity multiplier | 1.08 | 1.10 | 1.08 | 1.06 | 1.06 | 1.45 | 1.34 | 1.28 | 1.39 | 1.40 |
| Liabilities / Assets | 0.08 | 0.09 | 0.07 | 0.06 | 0.06 | 0.31 | 0.25 | 0.22 | 0.28 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -19.4% | - | -87.2% | -67.6% | -19.8% | - | -7.4% | -2.0% | -12.2% | - |
| Net income growth (YoY) | -13.8% | - | -79.7% | -57.4% | -18.6% | - | -3.6% | 3.4% | -6.3% | - |
| EPS growth (YoY) | 48.3% | - | 47.5% | 54.1% | 31.0% | - | 20.0% | 26.0% | -425.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -18.3% | - | - | - | -10.5% | - | - | - | -25.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -35.8% | 260.6% | 207.2% | 188.8% | 304.5% | -36.4% | -28.8% | -19.8% | -46.0% | -39.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Regulus Therapeutics Inc. against the 5 most active filers in the same SIC group.